BridgeMD
Antiplatelet therapy after successful percutaneous coronary intervention for chronically occluded coronary artery: A prospective, multicentre, randomized study comparing two durations of dual antiplatelet therapy
EU CTIS ID: 2023-508148-23-01
What this study is testing
To assess the efficacy of a short DAPT of 1 month, in comparison with usual long DAPT (6 to 12 months) on the incidence rate over 12 months of net adverse clinical events (bleeding and/or ischemic events) in patients treated by coronary angioplasty for chronic total occlusion
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients who underwent a successful coronary stent implantation for chronic coronary occlusion, eligible for long-term aspirin therapy and requiring a dual antiplatelet therapy
- Affiliated to Social Security system
- Signature of informed consent
- Age > 18 years old
You likely can't join if
- Dual antiplatelet therapy contra-indication
- Patient with hypersensitivity to aspirin (or any of its excipients) and/or to any of the active substance or to any of the excipients of the investigational medical product used in this study (clopidogrel)
- Patient with contraindication to aspirin and/or clopidogrel
- No coronary stent implanted
- Age<18years
- Patient under guardianship
See the full eligibility criteria
- Patients who underwent a successful coronary stent implantation for chronic coronary occlusion, eligible for long-term aspirin therapy and requiring a dual antiplatelet therapy
- Affiliated to Social Security system
- Signature of informed consent
- Age > 18 years old
- Dual antiplatelet therapy contra-indication
- Patient with hypersensitivity to aspirin (or any of its excipients) and/or to any of the active substance or to any of the excipients of the investigational medical product used in this study (clopidogrel)
- Patient with contraindication to aspirin and/or clopidogrel
- No coronary stent implanted
- Age<18years
- Patient under guardianship
- Pregnancy or breast feeding
- Prasugrel or ticagrelor use
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.